Biocon Ltd

Mid Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Biocon's subsidiary, Biocon Pharma, has received U.S. FDA approval for Liraglutide Injection, a generic version of Victoza, expanding its diabetes treatment portfolio.

Biocon Secures FDA Approval for Diabetes Treatment - 12 Mar, 2026

The FDA has reduced regulations for drug companies, allowing them to produce cheaper versions of expensive biologic drugs, which may benefit Biocon Ltd.

FDA Eases Rules for Biologic Drug Manufacturers - 09 Mar, 2026

Jefferies has maintained a 'Hold' rating on Biocon Ltd, setting a target price of Rs 360. This reflects cautious sentiment towards the stock's performance.

Jefferies Maintains Hold on Biocon with Target Price - 05 Mar, 2026

Biocon Ltd has completed the acquisition of Optionally Convertible Redeemable Non-Cumulative Preference Shares (OCRPS) in its subsidiaries, investing a total of Rs 315 crore.

Biocon Completes Significant Investment in Subsidiaries - 04 Mar, 2026

Biocon Ltd's stock has gained for five consecutive sessions, rising 0.99% today. The company received USFDA approval for its generic weight-loss drug Liraglutide, marking a significant milestone in the US obesity treatment market.

Biocon Secures USFDA Approval, Stock Gains Continue - 25 Feb, 2026

Biocon Biologics anticipates strong FY27 as new biosimilars gain traction. Nuvama projects a target price of Rs 480, highlighting effective debt management and market share growth.

Biocon's Strong Outlook Driven by Biosimilars Growth - 20 Feb, 2026

Biocon outlines growth strategies and margin improvements while analysts provide mixed ratings, with target prices ranging from ₹360 to ₹445.

Biocon Updates: Growth Plans and Analyst Ratings - 16 Feb, 2026

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Mutual Funds have increased holdings from 13.75% to 17.03% in Jan 2026 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Up

In the last 6 months, BIOCON stock has moved up by 3.6%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Rise

Retail Investor have increased holdings from 16.33% to 23.69% in Jan 2026 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Up

Netprofit is up for the last 3 quarters, 31.4 Cr → 143.8 Cr (in ₹), with an average increase of 52.0% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Spike

In the last 1 year, BIOCON has outperformed top 5 stocks with highest market-cap in Biotechnology & Medical Research

This section gives you an insight into why this company has been the best in its industry for the last 1 year.

Best in 1 Year

In the last 3 years, Vimta Labs Ltd has given 193.3% return, outperforming this stock by 103.6%

This section gives you an insight into how the peers have performed as compared to this company in the last 3 years.

Against Peers

Foreign Institutions have decreased holdings from 7.39% to 7.14% in Jan 2026 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Down

Revenue is down for the last 2 quarters, 4.38K Cr → 4.29K Cr (in ₹), with an average decrease of 2.2% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Fall

Promoters have decreased holdings from 54.45% to 44.91% in Jan 2026 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Down

Nifty Healthcare

Nifty LargeMidcap 250

Nifty Midcap 100

BSE Healthcare

Nifty 500

BSE 200

Nifty Midcap 150

S&P BSE 400 MidSmallCap

BSE 500

S&P BSE 150 MidCap

S&P BSE 250 LargeMidCap

NIFTY PHARMA

Nifty 200

Nifty MidSmallcap 400

SBI Contra Fund Direct Growth

SBI Midcap Fund Direct Growth

SBI Large & Midcap Fund Direct Growth

ICICI Prudential Value Fund Direct Plan Growth

Kotak Large & Midcap Direct Growth

Biocon Ltd’s net profit jumped 472.91% since last year same period to ₹143.80Cr in the Q3 2025-2026. On a quarterly growth basis, Biocon Ltd has generated 70.18% jump in its net profits since last 3-months.

Name	Value	Action
MACD level (12,26)	-0.25	Bearish
CCI (20)	170.59	Bearish
RSI (14)	39.91	Neutral
Momentum (10)	-0.7	Bullish
ADI (14)	32.22	Bearish
Ultimate Oscillator (7,14,28)	12.71	Bearish

Name	Value	Action
SMA (20)	372.65	Bearish
EMA (20)	372.36	Bearish
VWMA (20)	372.31	Bearish
SMA (50)	372.48	Bearish
EMA (50)	372.53	Bearish
SMA (200)	373.4	Bearish
EMA (200)	374.38	Bearish
KAMA (200)	372.79	Bearish
DEMA (200)	371.29	Bullish

Biocon Ltd (BIOCON)

Summary

Overall

Oscillators

Moving Averages